Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Celsion Corporation
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Number of employees : 29 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Oncology Drugs0.500100%0.500100% 0%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States0.500100%0.500100% 0%
Managers
NameAgeSinceTitle
Michael H. Tardugno682014Chairman, President & Chief Executive Officer
Jeffrey Wayne Church622013CFO, Secretary & SVP-Investor Relations
Nicholas Borys, Dr.592017Chief Medical Officer & Senior Vice President
Khursheed Anwer, Dr.592015Chief Scientific Officer & Executive VP
Pok Yu Chow, Dr.662007Independent Director
Robert W. Hooper722013Independent Director
Alberto R. Martinez, Dr.692010Independent Director
Andreas Voss, Dr.602015Independent Director
Donald P. Braun, Dr.692015Independent Director
Jason G. Fewell, Dr.-2014Vice President-Preclinical Research
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,443,279 32,976,081 98.6% 334 0.0% 98.6%
Shareholders
NameEquities%
Lincoln Park Capital Fund LLC 1,581,429 4.76%
The Vanguard Group, Inc. 1,330,085 4.00%
Heights Capital Management, Inc. 1,139,110 3.43%
Renaissance Technologies LLC 687,253 2.07%
BlackRock Fund Advisors 645,413 1.94%
Two Sigma Investments LP 312,791 0.94%
Geode Capital Management LLC 212,358 0.64%
Michael H. Tardugno 187,700 0.56%
Worth Venture Partners LLC 178,500 0.54%
Susquehanna Financial Group LLLP 109,165 0.33%
Company contact information
Celsion Corp.
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648

Phone : +1.609.896.9100
Fax : +1.609.896.2200
Web : http://www.celsion.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Celsion Corporation
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
CELSION CORPORATION-65.56%21
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.60%39 515
BEIGENE, LTD.82.54%27 421
GENMAB A/S50.39%23 222
BIONTECH SE158.91%20 893
HUALAN BIOLOGICAL ENGINEERING INC.110.85%15 640
ARGENX SE53.06%12 350
MYOKARDIA, INC.205.14%11 859
SAREPTA THERAPEUTICS, INC.6.37%10 776
NEUROCRINE BIOSCIENCES, INC.-10.86%8 936
ASCENDIS PHARMA A/S12.16%8 302
MIRATI THERAPEUTICS, INC.43.52%8 237
BIOCON LIMITED49.68%7 073
EXELIXIS, INC.23.67%6 733
ACCELERON PHARMA INC.101.30%6 393
PEPTIDREAM INC.-12.41%5 894
ARROWHEAD PHARMACEUTICALS, INC.-10.58%5 802
ULTRAGENYX PHARMACEUTICAL INC.108.69%5 400